Individualised treatment for multidrug-resistant tuberculosis in New South Wales, Australia.
drug-resistant tuberculosis
management of MDR-TB
tuberculosis
Journal
Australian and New Zealand journal of public health
ISSN: 1753-6405
Titre abrégé: Aust N Z J Public Health
Pays: United States
ID NLM: 9611095
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
01
02
2021
received:
01
12
2020
accepted:
01
06
2021
pubmed:
27
7
2021
medline:
26
10
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) presents a major global health challenge. In high-income countries, treatment is individualised to optimise efficacy and reduce toxicity. We aimed to evaluate the outcomes of patients with MDR-TB receiving individualised antibiotic therapy in Australia. This retrospective cohort study was performed in the city of Sydney in Australia and included patients diagnosed with bacteriologically confirmed MDR-TB diagnosed between 2000 and 2016. The clinical characteristics of patients and treatment details were extracted from medical records. The incidence of adverse events and end-of-treatment outcomes were also evaluated. Fifty-five patients with MDR-TB were identified at TB clinics in seven hospitals. The median age was 32 years (interquartile range [IQR]: 27-36 years). The median duration of the intensive phase treatment was six months (IQR 6-7 months). All patients' treatment administration was directly observed. The commonest reported adverse event was ototoxicity (44%; 23/52) and successful treatment outcomes were achieved by 95% (52/55) of patients. This study demonstrated the high treatment success rate that can be achieved using individualised treatment for MDR-TB in a well-resourced setting. Implications for public health: The expansion of individualised therapy promises to contribute to MDR-TB control and advance the ambitious goal of TB elimination by 2035.
Identifiants
pubmed: 34309967
doi: 10.1111/1753-6405.13144
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
437-442Subventions
Organisme : Australian NHMRC Career Development Fellowship
ID : APP#1148372
Informations de copyright
© 2021 The Authors.
Références
World Health Organization. Global Tuberculosis Report 2019 [Internet]. Geneva (CHE) WHO: 2019 [cited 2021 Jun 16]. Available from: https://www.who.int/teams/global-tuberculosis-programme
World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva (CHE): WHO; 2014.
Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005;171(7):699-706.
World Health Organization. Definitions and Reporting Framework for Tuberculosis - 2013 Revision (Updated December 2014) [Internet]. Geneva (CHE): WHO; 2014. [cited 2021 Jun 16]. Available from: http://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf;sequence=1
Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: An individual patient data meta-analysis. Clin Infect Dis. 2014;59(10):1364-74.
Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1600803.
Barry C, Waring J, Stapledon R, Konstantinos A, National Tuberculosis Advisory Committee. Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell Q Rep. 2012;36(1):82-94.
Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet. 2018;392(10150):821-34.
World Health Organization. Global Tuberculosis Report 2014 [Internet]. Geneva (CHE): WHO; 2014 [cited 2021 Jun 16]. Available from: https://apps.who.int/iris/handle/10665/137094
Ho J, Byrne A, Linh NN, et al. Decentralized care for multidrug-resistant tuberculosis: A systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584-93.
Lange C, Aarnoutse R, Alffenaar J, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23:645-62.
Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: A cohort study in the Philippines. PLoS Med. 2006;3(9):e352.
Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-61.
Akcakir Y. Correlates of Treatment Outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): A Systematic Review and Meta-analysis [PhD Dissertation]. Montreal (CAN): McGill University Department of Epidemiology and Biostatistics; 2010.
Kibret KT, Moges Y, Memiah P, et al. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: A systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):7.
Francis JR, Manchikanti P, Blyth CC, et al. Multidrug-resistant tuberculosis in Australia, 1998-2012. Int J Tuberc Lung Dis. 2018;22(3):294-9.
NSW Tuberculosis Program, Communicable Diseases Branch. Tuberculosis in NSW - Surveillance Report 2018 [Internet]. Sydney (AUST): Health Protection NSW, 2019. [cited 2021 Jun 16]. Availabe from: https://www.health.nsw.gov.au/Infectious/tuberculosis/Publications/2018-tb-report.pdf
National Tuberculosis Advisory Committee multi-drug resistant tuberculosis: Information paper (October 2007). Commun Dis Intell Q Rep. 2007;31(4):406-9.
Communicable Diseases Cluster Prevention and Control Department. WHO Meeting to Co-ordinate the DOTS-plus Workplan on Pilot Projects for the Management of Multidrug Resistant (MDR) Tuberculosis (TB) [Internet]. Geneva (CHE): World Health Organization; 1999 [cited 2021 Jun 16]. Availabe from: http://apps.who.int/iris/bitstream/handle/10665/65401/WHO_CDS_CPC_TB_99.262.pdf?sequence=1
WHO Global Tuberculosis Programme. WHO Treatment Guidelines for Drug-resistant Tuberculosis, 2016 Update. October 2016 Revision [Internet]. Geneva (CHE): World Health Organization; 2016 [cited 2021 June 16]. Availabe from: https://www.who.int/publications/i/item/9789241549639
National Cancer Institute. Common Terminology Criteria for Adverse Events V4.03 (CTCA). Washington (DC): U.S. Department of Health and Human Services; 2010.
Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9(6):640-5.
Günther G, Lange C, Alexandru S, et al. Treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med. 2016;375(11):1103-5.
Bright A, et al. Tuberculosis notifications in Australia, 2015-2018. Commun Dis Intell (2018). 2020;44.
Pontali E, Raviglione MC, Migliori GB. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. Eur Respir Rev. 2019;28(152):190035.
World Health Organization. The Global Plan to Stop TB 2011-2015: Transforming the Fight Towards Elimination of Tuberculosis [Internet]. Geneva (CHE): WHO; 2010 [cited 2021 Jun 16]. Availabe from: https://apps.who.int/iris/handle/10665/44437
Therapeutic Goods Administration. Medicines and Vaccines Post-market Vigilance, Statistics for 2017. V1.0 [Internet]. Canberra (AUST): Australian Government Department of Health; 2018 [cited 2021 Jun 16]. Availabe from: https://www.tga.gov.au/sites/default/files/medicines-and-vaccines-post-market-vigilance-statistics-2017.pdf
World Health Organization. Rapid Communication: Key Changes to Treatment of Multidrug- and Rifampicin-resistant Tuberculosis (MDR/RR-TB) [Internet]. Geneva (CHE): WHO; 2018 [cited 2021 Jun 16]. Availabe from: https://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf
World Health Organization Director-General. Ending Tuberculosis Progress in Implementing the Global Strategy and Targets for Tuberculosis Prevention, Care and Control After 2015 (the End TB Strategy) [Report] [Internet]. Geneva (CHE): WHO; 2019 [cited 2021 Jun 16]. Availabe from: https://apps.who.int/gb/ebwha/pdf_files/EB146/B146_10-en.pdf